VIDEO: Microbiome therapeutics promising for recurrent C. difficile
Click Here to Manage Email Alerts
In this video, Jessica R. Allegretti, MD, MPH, discussed a presentation from the ACG Annual Scientific Meeting that provided an overview of microbiome therapeutics currently under investigation for Clostridioides difficile infection.
During his presentation, Sahil Khanna, MBBS, MS, professor of medicine at the Mayo Clinic in Rochester, Minnesota, showed data on RBX2660 (Rebiotix Inc.), SER-109 (Seres Therapeutics) and CP101 (Finch Therapeutics) and VE303 (Vedonta Biosciences) in patients at risk for recurrent C. difficile.
“The take home points from this presentation are that fecal microbiota transplantation is effective and safe … but what we’re seeing is this move towards standardized microbiome products that are going through more traditional phase 2 and 3 paths, and we’re seeing positive data coming out of these programs,” Allegretti, director of the fecal microbiota center at Brigham and Women’s Hospital, told Healio. “As clinicians, it’s a very exciting space because we’re going to have a lot of options to treat our patients in the future.”
Reference
Khanna S. The future of microbiota restoration in C. difficile infections. Presented at: ACG Annual Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Collapse
Read more about
Click Here to Manage Email Alerts